Federal Research Clinical Center of Federal Medical & Biological Agency, Russia Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2013
NCT02594839
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Idiopathic Interstitial Pneumonias (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Pneumonia (Phase 2)

Pulmonary Fibrosis (Phase 2)

Spinal Cord Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2